Regulatory setback for one biotech contrasts with a major success in sleep disorder treatment, underscoring the high stakes …
Regulatory setback for one biotech contrasts with a major success in sleep disorder treatment, underscoring the high stakes …
Early results from a multi-centre trial indicate that BI-8721 may slow cognitive decline and reduce amyloid biomarkers in …
Major change in NIH policy mandates inclusion of organoids, computational models, or other non-animal methods in proposals, likely …
Adding atezolizumab to FOLFOX chemotherapy after surgery boosts disease-free survival in patients with surgically resected mismatch repair deficient …
In the UK DANTE trial stopping immunotherapy at 12 months produces disease control rates comparable to two-year treatment …
Several Phase 1 and Phase 2 trials report encouraging results this month, amplifying momentum in precision psychiatry, respiratory …
The European Commission launched several new funding opportunities under its Horizon Europe “Health” cluster to boost innovation in …
Phase III SEQUOIA-HCM analyses show aficamten offers benefit to patients with varying symptom severity and across regions, opening …
Regulatory nod gives push to a potentially powerful combination in acute myeloid leukaemia
Combination of avutometinib and defactinib offers new option where chemotherapy has often failed
Already a subscriber? Log in